

#5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Marsha A. Moses, Michael R. Freeman and Dmitri Wiederschain
Serial No.: 09/469,637
Filed: December 22, 1999
For: NON-INVASIVE ENZYME SCREEN FOR TISSUE REMODELLING-ASSOCIATED CONDITIONS
Attorney Docket No.: CMZ-083CPCN

Group Art Unit: N/A
Examiner: N/A



Assistant Commissioner For Patents
Washington, D.C. 20231

Certificate of First Class Mailing (37 CFR 1.8(a))
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents Washington, D.C. 20231 on the date set forth below.
2/19/00
Date of Signature and of Mail Deposit
By: [Signature]
Elizabeth A. Hanley
Reg. No. 33,505

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicant and their attorney are aware of the publications and information listed on the attached PTO Forms 1449, and in accordance with 37 C.F.R. §1.97 hereby submit these publications for the Examiner's consideration. In accordance with 37 C.F.R. § 1.98(d), no copies of the publications are enclosed. This Disclosure Statement presents publications that are of record in U.S. Application No. 08/843,095

Serial No.: 09/469,63

- 2 -

Group Art Unit: N/A

#5


of which this application is a continuation application. Copies of any publication cited herein will be provided upon request.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, the Applicant understands the Examiner will make an independent evaluation of the cited publications.

Under 37 C.F.R. § 1.97(b)(3), no additional costs are believed to be due in connection with the filing of this disclosure. If, however, a first Office Action on the merits issues in this application bearing a mailing date prior to the date of this Information Disclosure Statement, please charge the appropriate fee as required under 37 CFR 1.17(p) to our Deposit Order Account No. 12-0080.

Respectfully submitted,

LAHIVE & COCKFIELD, LLP



Elizabeth A. Hanley
Registration No. 33,505
Attorney for Applicant

28 State Street
Boston, MA 02109
(617) 227-7400

Date: 2/18/00

[Handwritten initials]

APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-80	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO CME-083CPCN	SERIAL NO. 09/469,637
LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT Marsha A. Moses et al.	
		FILING DATE December 22, 1999	GROUP

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA	5,270,447	12/93	Liotta et al.	530	326	
AB	5,324,634	06/94	Zucker	435	7.23	
AC	5,344,760	09/94	Harvey et al.	435	7.5	
AD	5,482,848	01/96	Dickson et al.	435	219	

FOREIGN PATENT DOCUMENTS

	EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AE	685 557	06/95	EPO				
	AF	691 409	10/96	EPO				
	AG	WO 90/10228	09/90	PCT				
	AH	EP 0 430 642	06/91	EPO				
	AI	WO 91/11714	08/91	PCT				
	AJ	JP 03 290 199	12/91	Japan			abst	
	AK	WO 92/01936	02/92	PCT				
	AL	WO 94/25434	11/94	PCT				
	AM	WO 93/20447	10/93	PCT				




OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

	AN	Attallah, A. et al., "Comparative Study Between Cytology and Dot-ELISA for Early Detection of Bladder Cancer", <i>A.J.C.P.</i> , Vol. 102, No. 1, pp. 109-114 (1996);
	AO	Basta, M. et al., "Cytokeratin Shedding in Urine: A Biological Marker for Bladder Cancer?", <i>British Journal of Urology</i> , Vol. 61, pp. 116-121 (1988);
	AP	Blaser, J. et al., "A Sandwich Enzyme Immunoassay for the Determination of Neutrophil Lipocalin in Body Fluids", <i>Clinica Chimica Acta</i> , Vol. 235, pp. 137-145 (1995);
	AQ	Bogdanowicz, J. et al., "Evaluation of Prostate-Specific Antigen and Prostatic Acid Phosphatase in Untreated Prostatic Carcinoma and Benign Prostatic Hyperplasia", <i>Scand. J. Urology Nephrol. Suppl.</i> , Vol. 138, pp. 97-103 (1991);
	AR	Braunhut, S. et al., "Retinoids Modulate Endothelial Cell Production of Matrix-degrading Proteases and Tissue Inhibitors of Metalloproteinases (TIMP)", <i>Journal of Biological Chemistry</i> , Vol. 259 (18):13472-13479 (1994);
	AS	Breul, J. et al., "Prostate-Specific Antigen in Urine", <i>Eur. Urol.</i> , Vol. 26, pp 18-21 (1994);

Examiner	Date Considered
*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-80	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO CME-083CP	SERIAL NO. 08/843,095
		LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)	
		APPLICANTS Marsha A. Moses et al.	
		FILING DATE April 25, 1997	GROUP



OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

BA	Carr, M. et al., "Urinary Levels of the Renal Tubular Enzyme N-Acetyl-β-D-Glucosaminidase in Unilateral Obstructive Uropathy", <i>The Journal of Urology</i> , Vol. 151, pp. 442-445 (1994);
BB	Fernandez-Luna, J. et al., "Measurement of Protein HC (α ₁ microglobulin) and protein HC-IgA complex in different body fluids", <i>J. Clin. Pathol.</i> , Vol. 41, pp. 1176-1179 (1988);
BC	Fine, R., et al., "Accumulation of Urinary Cancer-related Glycoprotein, EDCl, in Psoriasis", <i>Journal of Investigative Dermatology</i> , Vol. 73, pp. 264-265 (1979);
BD	Garnick, M. , "Prostate Cancer: Screening, Diagnosis, and Management", <i>Annals of Internal Medicine</i> , Vol. 118, pp. 804-818 (1993);
BE	Garnick, M. , "The Dilemmas of Prostate Cancer", <i>Scientific American</i> , Vol. 270 (4), pp. 72-81 (1994);
BF	Grover, P. et al., "Analysis of Prostatic Fluid: Evidence for the Presence of a Prospective Marker for Prostatic Cancer", <i>The Prostate</i> , Vol. 26, pp. 12-18 (1995);
BG	Ho, K. et al., "Urinary Beta-Glucuronidase Activity as an Initial Screening Test for Urinary tract Malignancy in High Risk Patients", <i>Cancer</i> , Vol. 76, No. 3, pp. 473-478 (1995);
BH	Jones, A. et al., "Urinary N-acetyl-β-glucosaminidase Activity in Type I Diabetes Mellitus", <i>Ann Clin Biochem</i> , Vol. 32, pp. 58-62 (1995);
BI	Kossakowska, A. et al., "Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) RNA Is Expressed at Elevated Levels in Malignant Non-Hodgkin's Lymphomas", <i>Blood</i> , Vol. 77 (11), pp. 2475-2481 (1991);
BJ	Lee, M. et al., "Analysis of Affinity and Structural Selectivity in the Binding of Proteins to Glycosaminoglycans: Development of a Sensitive Electrophoretic Approach", <i>Biochemistry</i> , Vol. 88, pp. 2768-2772 (1991);
BK	Liotta, L. et al., "Cancer Metastasis and Angiogenesis: An Imbalance of Positive and Negative Regulation", <i>Cell</i> , Vol. 64, pp. 327-336 (1991);
BL	Lu, X. ET AL., "Immunological Quantitation of Levels of Tissue Inhibitor of Metalloproteinase-1 in Human Colon Cancer", <i>Cancer Research</i> , Vol. 51, pp. 6231-6235 (1991);
BM	Margulies, I. et al. "Urinary Type IV Collagenase: Elevated Levels Are Associated with Bladder Transitional Cell Carcinoma" <i>Cancer Epidemiology, Biomarkers & Prevention</i> , Vol. 1, pp. 467-474 (1992);
BN	Miller, D. et al., "Purification and Characterization of Active Human Interleukin 1β-converting Enzyme from THP.1 Monocytic Cells", <i>Journal of Biological Chemistry</i> , Vol. 268 (24), pp. 18062-18069 (1993);
BO	Moses, M. et al., "Production of Matrix Metalloproteinases and a Metalloproteinase Inhibitor by Swarm Rat Chondrosarcoma", <i>Biochemical and Biophysical Research Communications</i> , Vol. 199 (1), pp. 418-424 (1994);

Examiner	Date Considered
----------	-----------------

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

